Ann: Appendix 4C - Quarterly Report & Brief Company Update, page-28

BRI Pharmaceutical Research Inc to reformulate monepantel..


"To address these issues, we have selected BRI to prepare a fully optimised MPL formulation that meets the exacting requirements for scaled manufacture, late-stage clinical trials and ultimately registration. BRI will address the taste issues associated with Zolvix, and increase the amount of MPL contained in each tablet or capsule to facilitate higher dosing."

After reading The BRI website, the Taste issues and Stronger Dosage don't seem to be insurmountable. From what I have read BRI take chemical formulations and make them palatable for multiple companies?
The important factor here is that PAA have contracted BRI to overcome Taste , Dose, Palatability and also meets the exacting requirements for Scaled Manufacture.
From my reading it would seem that this is the core business for BRI. The question should be "what timeframe does BRI require to overcome these issues?"